Some studies even suggest that the appearance of skin conditions such as epidermal growth factor inhibitor (EGFRI) toxicity‐related skin rash could potentially be a predictive marker for treatment efficacy, since they reflect drug concentration and activity.19, 32, 33, 34, 35. This evidence concerns the gene EGF and exanthem.